Who Buys Antitoxin from India — 238 Importers Behind a $13.3M Market

The buyer landscape for Antitoxin imports from India encompasses several distinct segments:

1. Government Procurement Agencies: Entities like the World Health Organization (WHO) and Médecins Sans Frontières (MSF) fall into this category. They procure Antitoxins for large-scale public health initiatives, often through international tenders. Their purchasing patterns are characterized by bulk orders aligned with programmatic needs and funding cycles. For instance, WHO's procurement for Pakistan amounted to $0.47 million, while MSF's logistics unit in France accounted for $0.42 million.

2. Distributors: Companies such as Planet Pharma in France ($0.39 million) and SFSMN in Sudan ($0.49 million) serve as intermediaries, supplying Antitoxins to healthcare providers and pharmacies. Their orders are typically regular and based on market demand forecasts, ensuring a steady supply chain to meet ongoing needs.

3. Hospital Groups: While specific hospital groups are not explicitly listed among the top buyers, it's common for such entities to procure Antitoxins directly for patient care. Their purchasing behavior often involves consistent orders to maintain adequate stock levels for emergency treatments.

4. Re-exporters: Entities in the United Arab Emirates, such as the WHO Warehouse ($0.40 million), may act as re-exporters, distributing Antitoxins to neighboring regions. Their order patterns are influenced by regional demand and logistical considerations.

5. Contract Manufacturers: While not explicitly identified in the top buyer data, contract manufacturers may procure Antitoxins for formulation into final products or for inclusion in combination therapies. Their purchasing is typically project-based and aligned with production schedules.

Understanding these segments and their purchasing behaviors is crucial for tailoring market strategies and ensuring efficient supply chain management.

France

1. Drug Regulatory Authority: Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM).

2. Import Registration Process for Antitoxin: Importers must obtain an Economic Operator Registration and Identification (EORI) number and submit a Single Administrative Document (SAD) to French customs. The ANSM requires a marketing authorization for medicinal products, which involves submitting a dossier demonstrating the product's quality, safety, and efficacy.

3. Estimated Timeline for Registration: The marketing authorization process can take approximately 210 days, depending on the completeness of the application and any additional information requests.

4. Import Tariff/Duty for HS 30021220: Pharmaceutical products under HS code 30021220 are generally subject to a 0% import duty within the European Union.

Morocco

1. Drug Regulatory Authority: Direction du Médicament et de la Pharmacie (DMP) under the Ministry of Health.

2. Import Registration Process for Antitoxin: Importers must register the product with the DMP, providing documentation on the product's quality, safety, and efficacy. A local representative is often required to facilitate the registration process.

3. Estimated Timeline for Registration: The registration process typically takes between 6 to 12 months, depending on the complexity of the dossier and regulatory workload.

4. Import Tariff/Duty for HS 30021220: Pharmaceutical products may be subject to import duties; however, specific rates can vary. It's advisable to consult the latest Moroccan customs tariff schedule for precise information.

United Arab Emirates

1. Drug Regulatory Authority: Ministry of Health and Prevention (MOHAP).

2. Import Registration Process for Antitoxin: Importers must register both the product and the manufacturing site with MOHAP. The process includes submitting detailed documentation and may require local testing.

3. Estimated Timeline for Registration: The registration process can take approximately 6 to 9 months, subject to the completeness of the application and any additional requirements.

4. Import Tariff/Duty for HS 30021220: Pharmaceutical products are generally exempt from import duties in the UAE.

Sudan

1. Drug Regulatory Authority: National Medicines and Poisons Board (NMPB).

2. Import Registration Process for Antitoxin: Importers must obtain a registration certificate from the NMPB, which involves submitting comprehensive product information and samples.

3. Estimated Timeline for Registration: The registration process may take 12 months or more, depending on the regulatory review process and any additional information requests.

4. Import Tariff/Duty for HS 30021220: Import duties for pharmaceutical products can vary; it's recommended to consult the latest Sudanese customs tariff schedule for accurate rates.

Indonesia

1. Drug Regulatory Authority: Badan Pengawas Obat dan Makanan (BPOM).

2. Import Registration Process for Antitoxin: Importers must register the product with BPOM, providing detailed documentation on the product's quality, safety, and efficacy. A local Indonesian company must act as the registration holder.

3. Estimated Timeline for Registration: The registration process typically takes 12 to 18 months, depending on the complexity of the product and the completeness of the application.

4. Import Tariff/Duty for HS 30021220: Pharmaceutical products may be subject to import duties; specific rates should be verified with the latest Indonesian customs tariff schedule.

The demand for Antitoxins in importing countries is primarily driven by the prevalence of diseases such as tetanus and diphtheria, which require prompt administration of Antitoxins for effective treatment. For instance, according to the World Health Organization (WHO), there were approximately 12,000 reported cases of tetanus worldwide in 2024, underscoring the ongoing need for these critical treatments.

Government healthcare programs and the expansion of universal health coverage also significantly contribute to the demand. Many countries have included Antitoxins in their national essential medicines lists, aligning with the WHO Essential Medicines List, which facilitates procurement through international tenders and bulk purchasing agreements. The presence of 238 buyers across 80 countries, as per TransData Nexus data, indicates a broad and sustained market opportunity for Antitoxin suppliers.

The buyer landscape for Antitoxin imports from India encompasses several distinct segments:

1. Government Procurement Agencies: Entities like the World Health Organization (WHO) and Médecins Sans Frontières (MSF) fall into this category. They procure Antitoxins for large-scale public health initiatives, often through international tenders. Their purchasing patterns are characterized by bulk orders aligned with programmatic needs and funding cycles. For instance, WHO's procurement for Pakistan amounted to $0.47 million, while MSF's logistics unit in France accounted for $0.42 million.

2. Distributors: Companies such as Planet Pharma in France ($0.39 million) and SFSMN in Sudan ($0.49 million) serve as intermediaries, supplying Antitoxins to healthcare providers and pharmacies. Their orders are typically regular and based on market demand forecasts, ensuring a steady supply chain to meet ongoing needs.

3. Hospital Groups: While specific hospital groups are not explicitly listed among the top buyers, it's common for such entities to procure Antitoxins directly for patient care. Their purchasing behavior often involves consistent orders to maintain adequate stock levels for emergency treatments.

4. Re-exporters: Entities in the United Arab Emirates, such as the WHO Warehouse ($0.40 million), may act as re-exporters, distributing Antitoxins to neighboring regions. Their order patterns are influenced by regional demand and logistical considerations.

5. Contract Manufacturers: While not explicitly identified in the top buyer data, contract manufacturers may procure Antitoxins for formulation into final products or for inclusion in combination therapies. Their purchasing is typically project-based and aligned with production schedules.

Understanding these segments and their purchasing behaviors is crucial for tailoring market strategies and ensuring efficient supply chain management.

France

1. Drug Regulatory Authority: Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM).

2. Import Registration Process for Antitoxin: Importers must obtain an Economic Operator Registration and Identification (EORI) number and submit a Single Administrative Document (SAD) to French customs. The ANSM requires a marketing authorization for medicinal products, which involves submitting a dossier demonstrating the product's quality, safety, and efficacy.

3. Estimated Timeline for Registration: The marketing authorization process can take approximately 210 days, depending on the completeness of the application and any additional information requests.

4. Import Tariff/Duty for HS 30021220: Pharmaceutical products under HS code 30021220 are generally subject to a 0% import duty within the European Union.

Morocco

1. Drug Regulatory Authority: Direction du Médicament et de la Pharmacie (DMP) under the Ministry of Health.

2. Import Registration Process for Antitoxin: Importers must register the product with the DMP, providing documentation on the product's quality, safety, and efficacy. A local representative is often required to facilitate the registration process.

3. Estimated Timeline for Registration: The registration process typically takes between 6 to 12 months, depending on the complexity of the dossier and regulatory workload.

4. Import Tariff/Duty for HS 30021220: Pharmaceutical products may be subject to import duties; however, specific rates can vary. It's advisable to consult the latest Moroccan customs tariff schedule for precise information.

United Arab Emirates

1. Drug Regulatory Authority: Ministry of Health and Prevention (MOHAP).

2. Import Registration Process for Antitoxin: Importers must register both the product and the manufacturing site with MOHAP. The process includes submitting detailed documentation and may require local testing.

3. Estimated Timeline for Registration: The registration process can take approximately 6 to 9 months, subject to the completeness of the application and any additional requirements.

4. Import Tariff/Duty for HS 30021220: Pharmaceutical products are generally exempt from import duties in the UAE.

Sudan

1. Drug Regulatory Authority: National Medicines and Poisons Board (NMPB).

2. Import Registration Process for Antitoxin: Importers must obtain a registration certificate from the NMPB, which involves submitting comprehensive product information and samples.

3. Estimated Timeline for Registration: The registration process may take 12 months or more, depending on the regulatory review process and any additional information requests.

4. Import Tariff/Duty for HS 30021220: Import duties for pharmaceutical products can vary; it's recommended to consult the latest Sudanese customs tariff schedule for accurate rates.

Indonesia

1. Drug Regulatory Authority: Badan Pengawas Obat dan Makanan (BPOM).

2. Import Registration Process for Antitoxin: Importers must register the product with BPOM, providing detailed documentation on the product's quality, safety, and efficacy. A local Indonesian company must act as the registration holder.

3. Estimated Timeline for Registration: The registration process typically takes 12 to 18 months, depending on the complexity of the product and the completeness of the application.

4. Import Tariff/Duty for HS 30021220: Pharmaceutical products may be subject to import duties; specific rates should be verified with the latest Indonesian customs tariff schedule.

The demand for Antitoxins in importing countries is primarily driven by the prevalence of diseases such as tetanus and diphtheria, which require prompt administration of Antitoxins for effective treatment. For instance, according to the World Health Organization (WHO), there were approximately 12,000 reported cases of tetanus worldwide in 2024, underscoring the ongoing need for these critical treatments.

Government healthcare programs and the expansion of universal health coverage also significantly contribute to the demand. Many countries have included Antitoxins in their national essential medicines lists, aligning with the WHO Essential Medicines List, which facilitates procurement through international tenders and bulk purchasing agreements. The presence of 238 buyers across 80 countries, as per TransData Nexus data, indicates a broad and sustained market opportunity for Antitoxin suppliers.